While N‐glycan synthesis in the endoplasmic reticulum (ER) is relatively well conserved in
eukaryotes, N‐glycan processing and O‐glycan biosynthesis in the Golgi apparatus are …

Plant molecular pharming has emerged as a niche technology for the manufacture of
pharmaceutical products indicated for chronic and infectious diseases, particularly for …

Among the many plant-based production systems that have been developed for
pharmaceutical proteins, seeds have the useful advantage of accumulating proteins in a …

Recombinant proteins can be produced in a diverse array of plant-based systems, ranging
from whole plants growing in the soil to plant suspension cells growing in a fully-defined …

Thanks to their potential to bind virtually all types of molecules; monoclonal antibodies are in
increasing demand as therapeutics and diagnostics. To overcome the overloading of current …

In eukaryotes, class I α-mannosidases are involved in early N-glycan processing reactions
and in N-glycan–dependent quality control in the endoplasmic reticulum (ER). To investigate …

Plant‐based transient expression is potentially the most rapid and cost‐efficient system for
the production of recombinant pharmaceutical proteins, but safety concerns associated with …

There are major structural differences between plant and mammalian N-linked glycans, with
those from plants being immunogenic in most laboratory mammals and eliciting glycan …

Antibody 2G12 is one of a small number of human immunoglobulin G (IgG) monoclonal
antibodies exhibiting potent and broad human immunodeficiency virus‐1 (HIV‐1) …

Many different plant-based systems have been used to produce recombinant
pharmaceutical proteins but only a small number have made the leap from an experimental …